Novel tubulin-polymerization inhibitor derived from thalidomide directly induces apoptosis in human multiple myeloma cells: Possible anti-myeloma mechanism of thalidomide

International Journal of Molecular Medicine

Volumn 21, Issue 2, 2008, Pages 163-168

  Iguchi, Toyotaka ^a   Yachide Noguchi, Tomomi ^b   Hashimoto, Yuichi ^b   Nakazato, Sawako ^a   Sagawa, Morihiko ^a   Ikeda, Yasuo ^a   Kizaki, Masahiro ^a,c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

2 (2,6 diisopropylphenyl) 5 hydroxy 1H isoindole 1,3 dione; Multiple myeloma; Thalidomine; Tubulin polymerization inhibitor

Indexed keywords

2 (2,6 DIISOPROPYLPHENYL) 5 HYDROXY 1H ISOINDOLE 1,3 DIONE; 5 HYDROXYTHALIDOMIDE; CASPASE 3; DOXORUBICIN; DRUG METABOLITE; MICROTUBULE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; RHIZOXIN; THALIDOMIDE; THALIDOMIDE DERIVATIVE; UNCLASSIFIED DRUG; VINCRISTINE;

APOPTOSIS; ARTICLE; ASSAY; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL;

EID: 38949128693     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.2.163     Document Type: Article

References (20)

1. Hideshima T and Anderson KC: Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2: 927-937, 2002.
2. Kumar A, Loughran T, Alsina, M, Durie BG and Djulbegovic B: Management of multiple myeloma: a systemic review and critical appraisal of published studies. Lancet Oncol 4: 293-304, 2003.
3. Singhal S, Mehta J, Desikan R, Ayers D, Robertson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B, Siegel D and Crowley J: Anti-tumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
4. Weber D: Thalidomide and its derivatives: new promise for multiple myeloma. Cancer Control 10: 375-383, 2003.
5. Cavo M, Zamagni E, Tosi P, Cellini C, Cangini D, Tacchetti P, Testoni N, Tonelli M, de Vivo A, Palareti G, Tura S and Baccarani M: First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89: 826-831, 2004.
6. Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y-T, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI and Anderson KC: Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950, 2000.
7. Anderson KC: Lenalidomide and thalidomide: mechanism of action-similarities and differences. Semin Hematol 42: S3-S8, 2005.
8. Miyachi H, Azuma A, Ogasawara A, Uchimura E, Watanabe N, Kobayashi Y, Kato F, Kato M and Hashimoto Y: Novel biological response modifiers: phthalidomides with tumor necrosis factor-alpha production-regulating activity. J Med Chem 40: 2858-2865, 1997.
9. Hashimoto Y: Novel biological response modifiers derived from thalidomide. Curr Med Chem 5: 163-178, 1998.
10. Inatsuki S, Noguchi T, Miyachi H, Oda S, Iguchi T, Kizaki M, Hashimoto Y and Kobayashi H: Tubulin-polymerization inhibitors derived from thalidomide. Bioorg Med Chem Lett 15: 321-325, 2005.
11. Yanagawa T, Noguchi T, Miyachi H, Kobayashi H and Hashimoto Y: Tubulin polymerization inhibitors with a fluorinated plithalidomide skeleton derived from thalidomide. Bioorg Med Chem Lett 16: 4748-4751, 2006.
12. Gupta D, Treon SP, Shima Y, Hideshima T, Podar K, Tai YT, Lin B, Richardson P, Ralph P, Wu L, Payvandi F, Muller G, Stirling DI and Anderson KC: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 15: 1950-1961, 2001.
13. Bartlett JB, Dredge K and Dalgleish AG: The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 4: 314-322, 2004.
14. Yasui H, Hideshima T, Richardson PG and Anderson KC: Recent advances in the treatment of multiple myeloma. Curr Pharm Biotechnol 7: 381-393, 2006.
15. Richardson P, Hideshima T and Anderson KC: Thalidomide: emerging role in cancer medicine. Amin Rev Med 53: 629-657, 2002.
16. Jordan MA and Wilson L: Microtubules and actin filaments: dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 10: 123-130, 1998.
17. Kenealy M and Prince HM: Current status of new drugs for the treatment of patients with multiple myeloma. Int Med J 36: 781-789, 2006.
18. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB and Prince HM: Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24: 4507-4514, 2006.
19. Zangari M, Siegel E, Barlogie B, Anaissie E, Saghafifar F, Fassas A, Morris C, Fink L and Tricot G: Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy. Blood 100: 1168-1171, 2002.
20. Osman K, Comenzo R and Rajkumar SV: Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 344: 1951-1952, 2001.